The legal troubles and withdrawal of Guidant from the endovascular abdominal arotic aneurysm repair market may have cast a pall on public perception of the procedure, but competitors advancing new devices towards the market believe it just means a bigger piece of the pie for everyone.

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

Our updated graphic tracker of key developments from the leading vaccine candidates.